Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. Nov. 30, 2018. Graham Mullis.

Executive Summary

French diagnostics firm Novacyt made its second deal in recent months, to supply molecular assay panels to US-based Genesis Diagnostics. The company is intentionally pushing an aggressive deal strategy for 2018 to prepare for anticipated global-economy headwinds in 2019, CEO Graham Mullis explains here.

"In 2019, we expect Brexit to have a big impact on the market, and trade relations between US and China on the global economy, so these are things we are watching ... For now, we are working hard to get as many deals over the line before the end of the year.” –Graham Mullis, CEO, Novacyt SA
Click here for a free trial of Medtech Insight
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT124306

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel